More people may be at risk for developing COPD due to exposure to environmental irritants, such as heat waves and air ...

Last year, the FDA approved the biologic drug Dupixent to treat uncontrolled eosinophilic COPD. The approval marked a step ...

Increased perceived stress may cause worsened respiratory symptoms and decreased quality of life in people with chronic ...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 ...

Increased perceived stress may cause worsened respiratory symptoms and decreased quality of life in people with chronic obstructive pulmonary disease (COPD), according to a new study.

The findings, published in The Lancet Respiratory Medicine, suggest that dupilumab, when used alongside standard triple ...

It had been hoped that RA patients might actually benefit more from these drugs, known as immune checkpoint inhibitors (ICIs) ...

Researchers sought to determine the relationship among hospitalization for COPD exacerbation, AF burden, and risk for subsequent stroke.

Increased perceived stress may cause worsened respiratory symptoms and decreased quality of life in people with chronic obstructive pulmonary disease ...

Explore Regeneron's Q1 2025 earnings with updates on Dupixent growth, EYLEA challenges, FDA hurdles, and upcoming approvals.

The respiratory therapeutics market represents one of healthcare's largest commercial opportunities, projected to reach £44.1 ...

Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses exc ...